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Abstract
Many patients with left ventricular systolic dysfunction 
have concomitant mitral regurgitation (MR). Their 
symptoms and prognosis worsen with increasing 
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severity of MR. Percutaneous MitraClip® can be used 
safely to reduce the severity of MR even in patients 
with advanced heart failure and is associated with 
improved symptoms, quality of life and exercise 
tolerance. However, a few patients with very poor left 
ventricular systolic function may experience significant 
haemodynamic disturbance in the peri-procedural 
period. We present three such patients, highlighting 
some of the potential problems encountered and discuss 
their possible pathophysiological mechanisms and safety 
measures.
Key words: Mitral regurgitation; Mitral valve; Left 
ventricular systolic dysfunction; Chronic heart failure; 
MitraClip; Percutaneous
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Core tip: We described three patients with severe 
mitral regurgitation and very poor left ventricular 
systolic function undergoing percutaneous MitraClip 
treatment. These patients experienced haemodynamic 
instability peri-procedurally immediately upon reduction 
of their mitral regurgitation. These patients shared 
a few features such as right ventricular dysfunction 
and pulmonary hypertension which may help to 
identify those who may develop such peri-procedural 
haemodynamic compromise. Our cases highlight that 
although MitraClip is generally a safe procedure, there 
should not be complacency especially when treating 
patients with very poor left ventricular function. Extreme 
caution and vigilance should be exercised when treating 
such patients.
Loh PH, Bourantas CV, Chan PH, Ihlemann N, Gustafsson F, 
Clark AL, Price S, Di Mario C, Moat N, Alamgir F, Estevez-
Loureiro R, Søndergaard L, Franzen O. Catheter-based intervention 
for symptomatic patient with severe mitral regurgitation and 
very poor left ventricular systolic function - Safe but no room for 
complacency. World J Cardiol 2015; 7(11): 817-821  Available 
from: URL: http://www.wjgnet.com/1949-8462/full/v7/i11/817.
htm  DOI: http://dx.doi.org/10.4330/wjc.v7.i11.817
INTRODUCTION
Approximately 35%-50% of patients with left ventricular 
systolic dysfunction (LVSD) develop significant mitral 
regurgitation (MR)[1]. As the severity of MR increases, 
their symptom and prognosis worsen with a 5-year 
mortality up to 60% in those with severe MR[2]. Whether 
treating MR in these patients alters the prognosis 
or progression of LVSD is not known. Percutaneous 
intervention for mitral regurgitation is now possible and 
can reduce the severity of MR even in patients with 
advanced heart failure with associated improvement 
in symptoms, quality of life and exercise tolerance[3,4]. 
However, special consideration should be given to 
patients with very poor left ventricular (LV) systolic 
function who may have very fragile hemodynamics that 
can be easily disturbed. We present a series of cases 
which outline some potential concerns.
CASE REPORT
Case 1
A 72-year-old man presented with NYHA class III 
symptoms of heart failure and was found to have a 
dilated LV with severe LVSD and moderate-to-severe 
MR due to ischemic heart disease (IHD) (Table 1). 
He had previously undergone coronary artery bypass 
grafting, and had a history of cerebrovascular accident. 
Echocardiography demonstrated significant right 
ventricular (RV) impairment and moderately raised 
pulmonary arterial systolic pressure (PASP) (Table 1).
A centrally placed MitraClip reduced the severity 
of MR to mild. Although there was no change in blood 
pressure (BP) which was maintained in the region of 
96/50 mmHg, trans-esophageal echocardiogram (TEE) 
showed worsening of LV systolic function (LV ejection 
fraction < 10%) and spontaneous echo contrast in the 
LV. After reversal of general anaesthesia, he had an 
episode of ventricular fibrillation that was successfully 
defibrillated with a single biphasic DC shock. Adrenaline 
and dobutamine support had to be administered for 48 
h. At discharge, echocardiography demonstrated mild 
residual MR with LV ejection fraction (LVEF) returned to 
20%. His symptoms improved to NYHA II.
Case 2
A 78-year-old lady with severe MR, a dilated LV and 
severe LVSD secondary to IHD had persistent NYHA 
class III symptoms despite optimal medication and 
cardiac resynchronisation therapy (CRT) (Table 1). She 
had moderate aortic stenosis with a valve area of 1.4 cm2, 
moderate RV impairment and raised PASP (Table 1).
A centrally placed MitraClip successfully reduced 
the severity of her MR to mild. However, there was 
acute deterioration in her LV systolic function on TEE 
and a reduction in her cardiac output from 3.5 to 3.1 
L/min. Her BP dropped from 104/60 to 88/54 mmHg. 
The MitraClip was re-positioned and deployed more 
medially which left her with moderate MR but her LV 
function, cardiac output and BP recovered. At discharge, 
echocardiography showed residual moderate MR and 
LVEF 15%. Her symptoms improved to NYHA class II 
which was sustained at 1-mo follow-up.
Case 3
A 68-year-old man with severe LVSD due to idiopathic 
dilated cardiomyopathy had severe MR and persistent 
NYHA III-IV breathlessness despite optimal medication 
and CRT. He had RV dilation with mild RV systolic 
impairment and raised PASP (Table 1).
Initial placement of the MitraClip reduced the severity 
of his MR to trivial. However, there was worsening of 
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his LV systolic function on TEE with reduction in cardiac 
output from 4.9 to 4.3 L/min (Figure 1) and BP from 
116/55 to 97/42 mmHg. These gradually improved 
to baseline after a period of observation and the clip 
was deployed. Invasive hemodynamic study showed 
an immediate reduction in his pulmonary arterial 
systolic pressure from 57 to 46 mmHg and mean left 
atrial pressure from 32 to 24 mmHg. At discharge, his 
symptom improved to NYHA II with trivial MR and LVEF 
of 20% on TTE.
DISCUSSION
These cases suggest that although percutaneous 
intervention for MR can be safely performed in patients 
with poor LV systolic function[3,4], significant clinical 
deterioration can occur in those with very poor LV 
function. The exact mechanism is unclear but likely 
to be due to a complex interaction of various cardiac 
mechanics and haemodynamic factors. In clinical 
setting, the haemodynamic effects following acute 
reduction of MR has been poorly understood as most 
were extrapolated from surgical patients and can 
be confounded by factors such as cardioplegia and 
cardiopulmonary bypass. Siegel et al[5] evaluated 
the acute haemodynamic effects of MitraClip therapy 
in 107 patients and found that successful MitraClip 
treatment was associated with an increase in cardiac 
output, cardiac index and forward stroke volume with 
a reduction in LV end diastolic pressure and calculated 
peripheral vascular resistance. These haemodynamic 
changes were thought to reduce the risk of low cardiac 
output state following the reduction of MR. However, 
the mean LVEF in their study was approximately 60% 
and patients with significant LVSD was not represented 
in their study[5]. In a predominantly secondary MR 
cohort of 50 patients with overall lower normal range 
of cardiac index (CI) and mean LVEF approximately 
50%, Gaemperli et al[6] reported an improvement in 
CI following MitraClip. However, recent report suggests 
that afterload mismatch can manifest as early transient 
worsening of LV function following Mitraclip in patients 
with poorer LV function (mean LVEF 26%)[7]. 
It is likely that complex haemodynamic factors 
may be involved in patients with severe MR and 
significant LVSD, especially in those with very low 
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LVEF[8,9]. The LV contractility is regulated by the Frank-
Starling mechanism, force-frequency relationship and 
neurohormonal control. The effectiveness of the later 
two mechanisms is impaired in failing human heart but 
the Frank-Starling mechanism can be preserved even in 
end-stage heart failure[10]. In the failing ventricles, the 
maximum LV performance is achieved at much larger LV 
volumes than that of the normal ventricles. This shows 
the importance of the Frank-Starling mechanism as a 
vital compensatory mechanism to maintain LV systolic 
contraction in the presence of significant LVSD[11]. In 
an experimental model using dogs with chronic heart 
failure, a reduction of LV end-diastolic diameter to 
normal level by abrupt inferior vena caval occlusion led 
to further reduction in LV systolic function indicating 
that the increase in LV preload is crucial to maintain LV 
systolic function[12]. Therefore, an acute and significant 
reduction in MR may lead to a decrease in LV end-
diastolic volume (preload)[5], compromising the Frank-
Starling compensatory mechanism and causes further 
deterioration in the LV systolic performance. In a way, 
this may be similar to that observed in the Fontan 
circulation where preload is known to be the most 
important determinant of cardiac output especially in 
the presence of a dilated or impaired ventricle[13]. 
Another potential factor is the poorly understood 
“pop-off valve” concept[14]. It was suggested that in 
patients with poor LV function, there is a need for the 
ventricle to offload into the low-impedance left atrium. 
However, the improvement in the outcome of mitral 
valve surgery in patients with poor LV function and 
understanding in the importance of chordal preservation 
has disputed this concept[15-17]. Nevertheless, it may be 
relevant in patients with very poor LV systolic function 
experiencing acute and significant reduction in MR. In 
experimental canine model where an external LV-to-
left atrial shunt was created to mimic the effect of MR, 
acute shunt closure led to an increase in the LV mean 
systolic pressure and wall stress (afterload)[18,19]. Closure 
of the shunt was associated with an improvement in 
the haemodynamic state with reduction in LV end-
LVEF
(%)
LVEDD
(mm)
Severity 
of MR
Cause of 
MR
Mid RV 
diameter 
(mm)
RV systolic 
dysfun­ction­
PASP
(mmHg)
  Case 1 20 64 Moderate-
to-severe
Secondary 51 Severe 50
  Case 2 15 68 Severe Secondary 42 Moderate 65
  Case 3 20 70 Severe Secondary 45 Mild 65
Table 1  Echocardiographic characteristics of the patien­ts
LVEDD: Left ventricular end-diastolic diameter; LVEF: Left ventricular 
ejection fraction; MR: Mitral regurgitation; PASP: Pulmonary arterial 
systolic pressure; RV: Right ventricle.
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Figure 1  Cardiac output was measured by a Swan-Ganz thermodilution 
catheter inserted via the left femoral vein[8].
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in cardiac output suggests serious haemodynamic 
compromise. Therefore, cardiac output monitoring is 
important during the peri-procedural period. Surrogate 
findings such as lower central venous saturation, 
reduction in systolic blood pressure and the appearance 
of spontaneous echo contrast in the LV may indicate 
a decrease in cardiac output. Other information, such 
as mitral valve opening area, left atrial or pulmonary 
capillary wedge pressure, left ventricular pressure[9] and 
if available, contractility derived from a conductance 
catheter[21] might help assess the situation. Continuous 
observation of the haemodynamic response following 
provisional clip deployment but before final release 
allows the situation to be assessed and as in patient 
2, the clip to be repositioned if there is a persistent 
unfavourable hemodynamic response.
Adverse events may still develop some time after 
the procedure and so the patients should be monitored 
continuously until they have fully recovered from the 
acute effect of the procedure and general anaesthesia.
Patients with poor LV function and significant MR 
can benefit from percutaneous MitraClip treatment. 
However, some of them may experience significant 
acute hemodynamic disturbance peri-procedurally and 
caution is necessary when treating these patients.
COMMENTS
Case characteristics
Peri-procedural haemodynamic instability during percutaneous MitraClip in three 
patients.
Clinical diagnosis
Decreased cardiac output and blood pressure on invasive haemodynamic study.
Differential diagnosis
Afterload mismatch, access site bleeding, cardiac tamponde.
Laboratory diagnosis
Invasive hemodynamics and echocardiographic are the main diagnostic tools.
Imaging diagnosis
Trans-esophageal echocardiogram confirmed deteriorating left ventricular (LV) 
function and often with appearance of spontaneous echo contrast in the LV.
Treatment
Cautious and intensive haemodynamic support and monitoring before MitraClip 
deployment is effective in most cases; but rare cases may require repositioning 
of MitraClip to avoid substantial acute reduction of mitral regurgitation.
Related reports
Prior hemodynamic studies mainly limited to patients with better left ventricular 
ejection fraction. However, similar to this case series, Melisurgo et al reported a 
small group of patients with poor LV function experiencing afterload mismatch 
peri-procedurally.
Term explanation
“Pop-off valve” concept proposed that mitral regurgitation (MR) allows a degree 
of afterload reduction in the LV with poor systolic function and this is abolished 
upon acute reduction in the regurgitant volume. The resultant increase in LV 
afterload casues afterload mismatch leading to worsening LV function and 
diastolic pressure (LVEDP) and increased forward 
cardiac output. However, in the presence of severe LV 
systolic dysfunction, LVEDP increased (preload) despite 
a reduction in LV diastolic filling and the forward flow 
decreased[18]. The increase in LV systolic and diastolic 
wall stress leads to an increase in myocardial oxygen 
consumption; whilst increased LVEDP may reduce coro-
nary blood flow leading to relative subendocardial 
ischaemia[20]. This represents an experimental model 
which is not confounded by the effect of cardioplegia 
and cardiopulmonary bypass and may partly explain 
the adverse events in our patients. Since percutaneous 
MitraClip can be performed without cardiopulmonary 
bypass, the real-time beat-to-beat hemodynamic 
variables, LV function and MR severity can be assessed. 
This may help understand the pathophysiology of 
haemodynamic disturbance following acute MR redu-
ction in patients with significant LVSD.
Our patients shared some common features[7] which 
may have contributed to the acute adverse events. 
They had dilated LV with advanced LVSD (LVEF ≤ 
20%), pulmonary hypertension, RV systolic impairment 
and significant MR with substantial reduction following 
intervention. A cautious approach in managing the 
patients with very poor LV systolic function is obligatory, 
especially in the light of the surgical experience[1]. 
Every patient with significant LVSD should have 
individualised management within a multi-disciplinary 
team approach involving the interventional cardiologists, 
cardiac surgeons, cardiac anaesthetists and intensive 
care physicians, heart failure and imaging specialists 
and other paramedical members. Treatment strategies 
and options in case of procedural failure should be 
discussed. The patients should be pre-assessed tho-
roughly whilst receiving optimal heart failure therapy. 
TEE is mandatory to determine the anatomical suita-
bility for the procedure and cardiac catheterisation 
can provide accurate haemodynamic evaluation. The 
assessment of LV contractile reserve and RV function 
may be helpful[16]. 
Pre-procedurally, some patients may need stabili-
sation of their clinical state with intravenous diuretic 
and/or nitrate infusion. In patients at risk of significant 
haemodynamic disturbance during the procedure, pre-
procedural infusion of inodilators or insertion of intra-
aortic balloon pump (IABP) may be considered with 
close liaison with all who are involved in the care of the 
patient including the heart failure and intensive care 
teams.
During the procedure, LVEF may decrease immedi-
ately after the reduction of MR in some patients. Since 
LVEF represents a combination of forward stroke 
volume (SV) and regurgitant volume (RVol) of MR, 
reduction in the RVol may lead to a net increase in SV 
even if the LVEF reduces[5,9]. Without any significant 
changes in the heart rate, an increase in cardiac output 
and systolic blood pressure are signs of positive acute 
haemodynamic response. Conversely, a reduction 
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haemodynamic instability.
Experiences and lessons
Although MitraClip is beneficial, a minority of patients with very poor LV function 
and significant MR may experience significant acute hemodynamic disturbance 
peri-procedurally, especially in those with co-existing right ventricular dysfunction 
and pulmonary hypertension. Hence caution is necessary when treating these 
patients.
Peer-review
The article describes a group of patients with very poor LV function and severe 
secondary MR who may experience significant haemodynamic disturbance 
during percutaneous MitraClip treatment. Although it is a relatively safe 
procedure, there is no room for complacency and extreme caution needs to be 
taken when treating those patients with very poor LV function.
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